Hims & Hers Health Shares Plummet 7.9% on $2.4B Volume Ranking 29th in Liquidity Despite 73% Revenue Growth and Tripled Earnings as Market Doubts $2.3–2.4B Target

On August 6, 2025, Hims & Hers Health (HIMS) closed at $58.68, reflecting a 7.91% decline amid a 2.4 billion-dollar trading volume, a 61.34% drop from the prior day’s activity. The stock ranked 29th in market liquidity, signaling reduced investor interest. The company reported second-quarter revenues of $544.8 million, a 73% year-over-year increase but below the $552 million analyst forecast. Despite the revenue shortfall, net income surged to $42.5 million, tripling from the previous year. CEO Andrew Dudum emphasized the company’s growth in personalized care and confidence in its precision medicine model, though the stock’s volatility suggests market skepticism about meeting full-year targets of $2.3–2.4 billion in revenue.

Hims reiterated its annual sales outlook despite the quarterly miss, with strategic expansion into Canada through a new weight loss program. The move aligns with the availability of generic semaglutide, a key driver for demand. However, the stock’s recent performance, including a 29% rebound in July, contrasts with its sharp August decline, indicating mixed investor sentiment. Analysts noted strong subscriber growth but cautioned that earnings momentum remains fragile ahead of further catalysts.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.